The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
The peptide vaccine’s randomized Phase 2b trial did not establish a survival benefit across the full study population. Sponsor-reported findings in patients aged 65 and younger warrant further investigation.
The October 8 decision adds an immunotherapy option to chemotherapy for a molecularly defined group of patients. The supporting trial found better disease-free survival, alongside more severe adverse events.
Research published October 8 connects differences in canine lifespan with DNA methylation patterns, including changes around mobile genetic elements. The observational findings identify mechanisms to investigate, without establishing that changing those patterns extends life.
The REDEFINE 3 baseline report describes a large trial in people with established cardiovascular disease. It does not yet show whether the peptide combination prevents heart attacks, strokes or cardiovascular death.
A three-year observational analysis links sustained monitoring to improved glucose control and lower urine albumin. It does not establish that the devices preserve kidney filtration or prevent kidney failure.
Researchers connect longer lipid chains with aging and report lifespan gains from genetic manipulation in worms. The findings identify a research target, while benefits for human healthspan remain untested.
Researchers linked a specific brainstem-to-midbrain connection to reduced food intake in rodents. The findings clarify peptide signaling relevant to obesity research, while leaving human efficacy and tolerability unresolved.
A multinational study links prognosis more closely to liver scarring than weight category. The findings challenge reassurance based on normal body size alone.
The findings complicate attempts to treat biological aging as one process with a single measurable target.
New reproductive-aging research supports further investigation of the peptide. Its existing FDA approval does not establish a fertility benefit in women.
A randomized trial found higher six-month abstinence when financial rewards were added to cessation support for underserved adults. Absolute quit rates remained low, and longer-term health benefits were not established by this result.
Researchers linked declining protein recycling to impaired immune clearance of senescent cells. Experimental activation reduced their accumulation in aged mice, but human safety and healthspan benefits remain unestablished.